Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of subcutaneous (SC, or under the skin) Tecentriq® (atezolizumab). Tecentriq SC can be injected in…
GSK plc (LSE/NYSE: GSK) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of momelotinib for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms…
This year the Bayer Foundation is presenting their renowned Hansen Family Award to Professor Claudia Höbartner. The Hansen Family Award is presented alternating with the Otto Bayer Award every second year. Leading scientists working in German-speaking countries are recognized with the…
AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity AstraZeneca and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the treatment of obesity, type-2…
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has…
AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic Prostate Cancer AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the first patient was treated with 212Pb-ADVC001, a Targeted…
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that domvanalimab plus zimberelimab and chemotherapy…
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), which can treat the underlying cause of cystic fibrosis (CF) in ~90% of…
Moderna Tops BioSpace’s Best Places to Work Ranking for Third Consecutive Year Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace’s 2024 Best Places to Work report for the third consecutive year. We are…
Seagen Inc. (NASDAQ: SGEN) today announced the first presentation of data evaluating ADCETRIS® (brentuximab vedotin) in combination with an anti-PD-1 checkpoint inhibitor in non-small cell lung cancer (NSCLC) and melanoma, and shared preclinical data for an investigational CD30-directed antibody-drug conjugate (ADC)…
Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the global, randomised, double-blind…
GSK launches £6m programme to boost STEM career progression for young people from under-represented groups in the UK GSK plc today announced the launch of a £6m, 10-year STEM equity programme, designed to inspire and support the next generation of…
